65 Investor presentation First nine months of 2023 In STEP 4, people treated with se weight loss of up to 18.2% STEP 4 showed significantly greater weight loss post run-in than placeb % change in body weight 0 Randomisation -4 Placebo: -5.2% -8 -12 -10.5% -16 Semaglutide 2.4 mg: -1 -20 0 4 8 12 16 20 24 28 36 44 52 60 Time since initiation (weeks) Change in body weight in % depicts observed means since time of randomisation; trial product estimand; BMI: body mass index
Download PDF file